- Key mechanism paper retracted in 2025.
- Requires specialist literature-integrity review before any positive mechanistic or clinical claim.
A research summary can become misleading when it describes a well-known mechanism without checking whether the supporting paper remains reliable. Dihexa offers a concrete example. The 2014 paper linking its reported cognitive and synaptic effects to the HGF/c-Met system is marked as retracted in PubMed, with an April 2025 retraction notice. That status must accompany discussion of the paper. Retracted dihexa mechanism paper with retraction record 2025 retraction notice for dihexa mechanism paper
Why the notice changes the article
A retraction means the publication should not be used as ordinary affirmative support for its conclusions. It does not automatically settle every question about the compound or every separate experiment. It does require an evidence review to identify which claims depended on that work and whether independent, reliable studies support them.
Repeating a paper's abstract while omitting its retraction creates the impression of settled evidence. The problem is especially serious when an early mechanistic result is extended into claims about memory enhancement or treatment of neurodegenerative disease. Multiple websites repeating the same underlying citation do not constitute independent replication.
Explore the Inside AXON website.
Visit insideaxon.com Affiliated AXON website. Promotional placement, not scientific evidence or a product recommendation.Rebuild the evidence from the ground up
A useful review records the original report, notices of concern, corrections and retractions. It then checks distinct studies for independent laboratories, clearly identified materials, suitable controls and clinically meaningful outcomes. A proposed mechanism and a human benefit should be evaluated separately.
This article deliberately makes no affirmative claim that Dihexa improves cognition, reaches a therapeutic brain exposure or is safe for human use. The retraction record prevents a confident narrative based on the frequently cited mechanism paper. A specialist evidence audit is required before expanding the article into therapeutic discussion. Availability as a research chemical does not resolve these scientific questions or establish clinical suitability.
You might be wondering
Where this question leads.
Follow the source material.
Links are preserved from the supplied draft manuscripts. Linked sources may change. Regulatory wording needs a fresh specialist check before public launch.
- Retracted dihexa mechanism paper with retraction record →
- 2025 retraction notice for dihexa mechanism paper →
Review required before wider publication
- Scientific integrity and neuropharmacology review
Discover another part of the AXON network.
Visit axp.life Affiliated AXON website. Promotional placement, not scientific evidence or a product recommendation.Continue exploring with Discover AXON.
Visit discoveraxon.com Affiliated AXON website. Promotional placement, not scientific evidence or a product recommendation.








